

CORRECTION

Open Access



# Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials

Neil M Schultz<sup>1\*</sup>, Neal D Shore<sup>2</sup>, Simon Chowdhury<sup>3</sup>, Laurence H Klotz<sup>4</sup>, Raoul S Conception<sup>5</sup>, David F Penson<sup>6</sup>, Lawrence I Karsh<sup>7</sup>, Hongbo Yang<sup>8</sup>, Bruce A Brown<sup>1</sup>, Arie Barlev<sup>9,10</sup> and Scott C Flanders<sup>1</sup>

## Correction to Schultz et al. *BMC Urology* (2018) 18:77 DOI: 10.1186/s12894-018-0387-7

It has been highlighted that in the original article [1] there was a typesetting mistake in the Results – NNT in Strive section. This Correction article states the incorrect and correct sentence.

### Incorrect:

The NNT for rPFS at 2 year was 2.6 (upper, lower limits: 1.9, 4.0) and at 2 years was 3.0 (1.9, 7.2) when comparing enzalutamide and bicalutamide.

### Correct:

The NNT for rPFS at 1 year was 2.6 (upper, lower limits: 1.9, 4.0) and at 2 years was 3.0 (1.9, 7.2) when comparing enzalutamide and bicalutamide.

### Author details

<sup>1</sup>Astellas Pharma, Inc., 1 Astellas Way, Northbrook, IL 60062, USA. <sup>2</sup>Carolina Urologic Research Center, Myrtle Beach, SC, USA. <sup>3</sup>Guy's, King's, and St. Thomas' Hospitals, London, UK. <sup>4</sup>Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. <sup>5</sup>Urology Associates, P.C., Nashville, TN, USA. <sup>6</sup>Vanderbilt University Medical Center, Nashville, TN, USA. <sup>7</sup>The Urology Center of Colorado, Denver, CO, USA. <sup>8</sup>Analysis Group, Inc., Boston, MA, USA. <sup>9</sup>Medivation, Inc., San Francisco, CA, USA. <sup>10</sup>Pfizer, Inc., New York, NY, USA.

Received: 21 September 2018 Accepted: 21 September 2018  
Published online: 01 October 2018

### Reference

1. Schultz NM, et al. Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. *BMC Urol.* 2018;18:77.

\* Correspondence: [neil.schultz@stellas.com](mailto:neil.schultz@stellas.com)

<sup>1</sup>Astellas Pharma, Inc., 1 Astellas Way, Northbrook, IL 60062, USA  
Full list of author information is available at the end of the article

